Know Cancer

or
forgot password

National, Randomized, Phase II Study Comparing Efficacy of Weekly Administration of Paclitaxel in Monotherapy or in Combination With Topotecan or Carboplatin in Patients With Epithelial Ovarian Cancer in Early Relapse


Phase 2
18 Years
N/A
Not Enrolling
Female
Ovarian Cancer, Fallopian Tube Cancer, Malignant Tumor of Peritoneum

Thank you

Trial Information

National, Randomized, Phase II Study Comparing Efficacy of Weekly Administration of Paclitaxel in Monotherapy or in Combination With Topotecan or Carboplatin in Patients With Epithelial Ovarian Cancer in Early Relapse


The main purpose of this research study is to find out if treatment of early relapse of
ovarian or fallopian tube or peritoneal cancer with paclitaxel (Taxol*) weekly administered,
in lower doses in combination with topotecan (Hycamtin*) or carboplatin will improve
efficacy compared to weekly administration of paclitaxel in monotherapy. Tolerance in the
three groups will be compared.


Inclusion Criteria:



- Patients aged > 18

- Histologically proven diagnosis of cancer of the ovary, the fallopian tube or
peritoneum

- Peritoneal and/or nodes and/or visceral metastases

- Disease in progression under treatment or within 6 months after a first or second
platinum-based line

- A period of 3 weeks between last chemotherapy and inclusion

- Measurable disease (Response Evaluation Criteria in Solid Tumors [RECIST] criteria)
or cancer antigen (CA) 125 assessable disease (Gynecologic Cancer Intergroup [GCIG]
criteria)

- ECOG performance status < 2

- Life expectancy of at least 12 weeks

Exclusion Criteria:

- Previously received weekly administration of paclitaxel chemotherapy

- Involved in a trial within the last 30 days

- Previously received a bone marrow autogreffe or irradiation of the abdomen within 5
years, due to intensive chemotherapy

- Prior diagnosis of malignancy

- History of ischemic cardiopathy, congestive heart failure (New York Heart Association
[NYHA] > 2), arrhythmia, hypertension, or significant valvulopathy

- Pre-existing motor or sensory neurologic pathology or symptoms National Cancer
Institute (NCI) - Common Terminology Criteria for Adverse Events (CTCAE) grade > 2

- Bone marrow, renal, or hepatic insufficiency

- Severe active infection or occlusive or sub-occlusive disease

- History of symptomatic brain metastases

- Fertile women not using adequate contraceptive methods

- Pregnant or breast feeding women

- Hypersensitivity to compounds chemically related to paclitaxel, topotecan, or
carboplatin

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Progression-free survival of patients in the three groups

Principal Investigator

Laure Chauvenet, MD, PhD

Investigator Role:

Study Director

Investigator Affiliation:

Hôpital Hôtel Dieu

Authority:

France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Study ID:

CAR\TAXHY

NCT ID:

NCT00189566

Start Date:

April 2004

Completion Date:

April 2009

Related Keywords:

  • Ovarian Cancer
  • Fallopian Tube Cancer
  • Malignant Tumor of Peritoneum
  • Relapse within 6 months
  • Previously received taxane derivative
  • Neoplasms
  • Ovarian Neoplasms
  • Peritoneal Neoplasms
  • Fallopian Tube Neoplasms
  • Neoplasms, Glandular and Epithelial

Name

Location